SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. - Garrido-Castro AC; Kim SE; Li T; Desrosiers J; Nanda R; Abdou Y; Clark AS; Sacks RL; O'Connor T; Sinclair N; Lo S; Augdahl G; et al. (Annals of oncology : official journal of the European Society for Medical Oncology, 2026)